Proline-rich antimicrobial peptides inhibit bacterial protein synthesis through two distinct ribosome-binding mechanisms | Research

The takeaway

Proline-rich AMPs bind in the ribosomal tunnel to inhibit protein biosynthesis through two mechanisms: class I blocks elongation via A-site tRNA interference, class II disrupts termination, ribosome release, and 50S subunit assembly.

Two ribosome-targeting mechanisms
PrAMPs use distinct binding modes in the ribosomal tunnel to block either protein elongation or termination, offering multiple avenues for antibiotic development

What the researchers found

Two classes of PrAMP mechanisms identified: Class I blocks elongation (A-site tRNA interference, P-site CCA-end disruption), Class II disrupts termination, ribosome release, and 50S assembly. New rumidicin family with Trp-Phe dyad enhances activity. Multiple binding sites on ribosomes for Class II.

Why it matters

PrAMPs have the highest safety profiles among antimicrobial peptides because they target ribosomes (like many antibiotics) rather than membranes. Understanding their precise mechanisms enables rational design of more potent peptide antibiotics.

How the study worked

Review of structural studies (cryo-EM, X-ray crystallography) and functional analyses of PrAMP-ribosome interactions.

What this study cannot tell us

Mechanistic review of structural data; clinical development of PrAMP-based drugs is still early. Most data from in vitro ribosome studies. In vivo efficacy and pharmacokinetics need development.

How to read the evidence

Review of high-resolution structural studies and biochemical data. Strong mechanistic evidence.

When this study was published

Published in 2025; includes newest structural insights and rumidicin discovery.

The bigger picture

PrAMPs represent the most "antibiotic-like" antimicrobial peptides—targeting the same fundamental machinery (ribosomes) as many clinical antibiotics. Their distinct binding modes could overcome resistance to existing ribosome-targeting antibiotics.

Questions still open

Can rumidicin-based peptides be developed as clinical antibiotics?
Do PrAMPs cause cross-resistance with existing ribosome-targeting antibiotics?
Could PrAMP mechanism knowledge guide design of hybrid peptide-small molecule antibiotics?

Common questions

What makes proline-rich peptides special among antimicrobial peptides?

Unlike most AMPs that kill bacteria by destroying their membranes (which can also damage human cells), proline-rich peptides enter bacteria and jam their protein-making machinery (ribosomes). This makes them much safer for human cells while still being effective antibacterial agents.

Could these peptides become new antibiotics?

They are promising candidates. They target the same essential machinery (ribosomes) as many proven antibiotics but through different binding mechanisms, meaning they could work against bacteria that resist current drugs. Their high safety profile is a significant advantage for clinical development.

Read the original research

New Aspects of Protein Biosynthesis Inhibition by Proline-Rich Antimicrobial Peptides.

Biochemistry. Biokhimiia, 90(11), 1536-1552

View on PubMed ↗Publisher’s paper ↗

Citation

Shulenina, Olga V; Tolstyko, Eugene A; Konevega, Andrey L; Paleskava, Alena. (2025). New Aspects of Protein Biosynthesis Inhibition by Proline-Rich Antimicrobial Peptides.. Biochemistry. Biokhimiia, 90(11), 1536-1552. https://doi.org/10.1134/S0006297925602394